Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences (Nasdaq: ARTL) recently presented research at the ICRS Symposium highlighting the effectiveness of its lead compound, ART26.12, in managing chemotherapy-induced pain. Professor Saoirse O’Sullivan reported that ART26.12 demonstrated significant effectiveness in preventing and treating pain sensitivity without sedation, while also mitigating weight loss linked to chemotherapy. The company aims to pursue FDA consultations for ART26.12’s further development. This research opens potential pathways for addressing Chemotherapy-Induced Peripheral Neuropathy, a condition without approved therapies.
Artelo Biosciences (Nasdaq: ARTL) announced that Professor Saoirse O’Sullivan will present pre-clinical data on ART26.12, a fatty acid binding protein 5 inhibitor, at the International Cannabinoid Research Society Symposium on June 26, 2022. Gregory D. Gorgas, the company's CEO, expressed enthusiasm about sharing findings related to advancements in cancer treatment. Additionally, the William A. Devane Young Investigator of the Year Award will be presented at the event, recognizing significant contributions to cannabinoid research.
Artelo Biosciences (NASDAQ: ARTL) announced that CEO Gregory D. Gorgas will present at the LD Micro conference on June 7, 2022, at 2:30 PM PT. The event, held at Four Seasons Westlake Village, California, will feature live webcasting and replays available on their site. Artelo specializes in developing therapeutics targeting lipid-signaling pathways, addressing conditions like anorexia, cancer, PTSD, pain, and inflammation. The company emphasizes collaboration with experts and a focus on high-impact therapies.
Artelo Biosciences (NASDAQ: ARTL) announced that CEO Gregory D. Gorgas will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. Gorgas is scheduled for an in-person presentation on May 24, 2022, at 5:00 p.m. ET. The event will provide both virtual and in-person participation options, and the presentation will be webcast live, with a replay available. Artelo specializes in developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system.
Artelo Biosciences (NASDAQ:ARLT) will present at the MicroCap Rodeo Spring Into Action - Best Ideas Virtual Investor Conference, scheduled from May 16-20, 2022. CEO Gregory D. Gorgas will speak on May 16, 2022, at 2:00 p.m. ET, with a live webcast available for replay. Artelo focuses on developing therapeutics that modulate lipid-signaling pathways, targeting conditions like cancer and PTSD. Qualified investors can schedule one-on-one meetings for further discussions. For more details, visit www.artelobio.com.
Artelo Biosciences (Nasdaq: ARTL) reported financial and operational results for Q1 2022, maintaining approximately $23.5 million in cash and investments, expected to support operations into late 2023. The net loss increased to $2.0 million or $0.05 per share, compared to $1.7 million or $0.09 per share in Q1 2021. The company anticipates results from the Phase 1b CAReS trial concerning ART27.13, aimed at treating cancer-related anorexia, in Q3 2022. Ongoing collaborations and positive pre-clinical data were highlighted, with a focus on addressing cancer anorexia cachexia syndrome.
Artelo Biosciences (Nasdaq: ARTL) announced promising pre-clinical results for ART27.13, indicating its potential in treating cancer-related muscle degeneration (cachexia). Research from Trinity College Dublin reveals that ART27.13 acts as a G-Protein Coupled Receptor agonist, targeting both CB1 and CB2 receptors. This could address significant patient needs, as cachexia impacts up to 80% of advanced cancer patients. ART27.13 is currently involved in the ongoing CAReS study for cancer appetite recovery.
Artelo Biosciences (Nasdaq: ARTL) announced a collaboration with Dr. Richard K. Porter at Trinity College Dublin to explore the role of fatty acid binding protein (FABP) inhibition in cancer treatment. This partnership aims to enhance understanding of FABP inhibitors and their potential for various tumors, which could lead to new treatments targeting unmet medical needs. The research is expected to yield multiple data readouts over the next year, reinforcing ART26.12's promise in oncology while expanding its compound library for targeted therapies.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company, announced its invitation to present at the 2022 Virtual Growth Conference on March 28-30, hosted by Maxim Group LLC and M-Vest. The event will feature company presentations, including updates from CEO Gregory Gorgas. Attendees must register as M-Vest members to participate. Artelo focuses on developing therapeutics that target lipid-signaling pathways and the endocannabinoid system, aiming to address significant medical needs in areas like anorexia, cancer, PTSD, and pain management.
Artelo Biosciences (Nasdaq: ARTL) reported a cash balance of $25.6 million as of December 31, 2021, sufficient to fund operations into H2 2023. The company's net loss for the four-month period was $4.0 million, or $0.12 per share, an increase from a net loss of $2.1 million in the same period in 2020. Key milestones include upcoming Phase 1 data for their ART27.13 program targeting cancer-related anorexia, with significant commercial potential in a market valued over $2 billion. The UK classification of ART27.13 as a non-controlled substance enhances its clinical development prospects.